Fwd: The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive ... (PRWeb via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:27 AM
Subject: The Mesothelioma Victims Center Offers Victims Of Asbestos Related Cancer & Their Loved Ones The Most Comprehensive ... (PRWeb via Yahoo! News)
To: mesothelioma77@gmail.com


Americas Watchdog created the Mesothelioma Center as a way for victims, or the family members & loved ones of Mesothelioma victims to get help,very honest advice & tailor made assistance at no cost to the victim, or their family members.

Mon, 30 Jun 2008 07:01:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=122mkn5tq/*http%3A//news.yahoo.com/s/prweb/20080630/bs_prweb/prweb1062604_1
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Local Woman Takes One Last Flight (R News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:27 AM
Subject: Local Woman Takes One Last Flight (R News)
To: mesothelioma77@gmail.com


A Rochester family is desperately working to get their loved one home for what could be the last time. Kathy Sanger, 59, of Ontario is terminally ill with cancer. During a trip to Alaska, Sanger's illness took a turn for the worse.

Mon, 30 Jun 2008 02:58:39 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12474dgee/*http%3A//www.rnews.com/Story_2004.cfm?ID=62601&rnews_story_type=18
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Smoke ban often defied Downstate

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: Smoke ban often defied Downstate
To: mesothelioma77@gmail.com

TAYLORVILLE, Ill. - The sign on the door of the American Tap warns patrons not to smoke.

Mon, 30 Jun 2008 07:33:16 GMT

---

Source: http://www.chicagotribune.com/news/nationworld/chi-downstate-smokingjun30,0,2717342.story
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Cancer risk from cellphone use is still a matter for study (Los Angeles Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:27 AM
Subject: Cancer risk from cellphone use is still a matter for study (Los Angeles Times)
To: mesothelioma77@gmail.com


Mon, 30 Jun 2008 07:38:57 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12o80ub87/*http%3A//www.latimes.com/technology/la-he-tumors30-2008jun30,0,6276503.story?track=rss
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Smoke-free policies are wide-ranging and extremely effective

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jun 30, 2008 at 6:26 AM
Subject: Smoke-free policies are wide-ranging and extremely effective
To: mesothelioma77@gmail.com

Smoke-free policies are reducing heart disease related to smoke exposure, the prevalence of smoking in adults and the exposure of both adults and children to second-hand smoke.

Mon, 30 Jun 2008 06:52:13 GMT

---

Source: http://www.nerve.in/news:253500143641
--
To unsubscribe from this feed, click here
To manage other subscriptions, click here
~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations.
To: mesothelioma77@gmail.com


[1]J Exp Clin Cancer Res. 2008 Mar; 27(1): 6
Spugnini EP, Crispi S, Scarabello A, Caruso G, Citro G, Baldi A

ABSTRACT: Malignant Mesothelioma is an uncommon and very aggressive tumor that accounts for 1% of all the deaths secondary to malignancy in humans. Interestingly, this neoplasm has been occasionally described in companion animals as well. Aim of this study was the preclinical evaluation of the combination of piroxicam with platinum-based intracavitary chemotherapy in pets. Three companion animals have been treated in a three years period with this combination. Diagnosis was obtained by ultrasonographic exam of the body cavities that evidenced thickening of the mesothelium. A surgical biopsy further substantiated the diagnosis. After drainage of the malignant effusion from the affected cavity, the patients received four cycles of intracavitary CDDP at the dose of 50 mg/m2 every three weeks if dogs or four cycles of intracavitary carboplatin at the dose of 180 mg/m2 (every 3 weeks) if cats, coupled with daily administration of piroxicam at the dose of 0.3 mg/kg. The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.



___
Source: http://www.hubmed.org/display.cgi?uids=18577247
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Paget disease of the humerus mimicking metastatic disease in a patient with metastatic malignant mesothelioma on whole body F-18 FDG PET/CT.
To: mesothelioma77@gmail.com


[1]Clin Nucl Med. 2008 Jul; 33(7): 510-2
Mahmood S, Martinez de Llano SR

A 71-year-old man with newly diagnosed malignant mesothelioma was referred for an F-18 FDG PET/CT study to evaluate the extent of disease. PET showed mild FDG uptake in the right chest, corresponding to a lobulated, mass-like right pleural effusion versus thickening involving the entire right pleural space, and some mediastinal involvement, on the accompanying CT scan. In addition, marked FDG uptake was seen in the proximal left humerus, suspicious for an osseous metastasis. The corresponding CT scan findings of cortical thickening and a "Swiss cheese" appearance were most consistent with Paget disease. The intense FDG uptake in an osseous lesion on FDG-PET in our case reminds us of the variable nature of FDG uptake in Paget disease, the possibility of false-positive findings on FDG-PET in patients with cancer, and the usefulness of the fusion techniques in the evaluation of skeletal lesions, with the potential for discriminating between benign Paget disease and other pathologic bone findings.



___
Source: http://www.hubmed.org/display.cgi?uids=18580246
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.

---------- Forwarded message ----------
From: HubMed - mesothelioma cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies.
To: mesothelioma77@gmail.com


[1]J Thorac Oncol. 2008 Jun; 3(6 Suppl 2): S131-4
Nikolinakos P, Heymach JV

Cediranib (AZD2171; Recentin, AstraZeneca, Wilmington, Delaware) is a once-daily oral tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1, 2, and 3, c-KIT, and platelet-derived growth factor receptors. In preclinical testing it inhibits tumor angiogenesis and inhibits tumor growth in a wide range of tumor models. Phase 1 studies show cediranib to be generally well tolerated as monotherapy at doses of 45 mg/d or less, with a pharmacokinetic profile that supports once-daily oral administration and toxic effects consistent with those seen in other agents that target the vascular endothelial growth factor pathway. Encouraging results from phase 1 studies as monotherapy or in combination with chemotherapy have prompted further investigation in several thoracic malignancies, including ongoing trials in malignant mesothelioma, small cell lung cancer, and an ongoing phase 2/3 trial in non-small cell lung cancer (NSCLC) in combination with chemotherapy. The NSCLC trials include patients with squamous cell histologic features and treated brain metastases, populations for which bevacizumab is currently not indicated. These trials will determine whether cediranib will join the growing armamentarium of therapeutic options for thoracic malignancies and broaden the number of patients with NSCLC who could potentially benefit from antiangiogenic therapy.



___
Source: http://www.hubmed.org/display.cgi?uids=18520296
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Effect of Raloxifene on Mammographic Density and Breast Magnetic Resonance Imaging in Premenopausal Women at Increased Risk for Breast Cancer.
To: mesothelioma77@gmail.com


[1]Cancer Epidemiol Biomarkers Prev. 2008 Jun 26;
Eng-Wong J, Orzano-Birgani J, Chow CK, Venzon D, Yao J, Galbo CE, Zujewski JA, Prindiville S

BACKGROUND: Mammographic density is a risk factor for breast cancer. Mammographic density and breast magnetic resonance imaging (MRI) volume (MRIV) assess the amount of fibroglandular tissue in the breast. Mammographic density and MRIV can be modulated with hormonal interventions, suggesting that these imaging modalities may be useful as surrogate endpoint biomarkers for breast cancer chemoprevention trials. We evaluated the effect of raloxifene on mammographic density and MRIV in premenopausal women at increased risk for breast cancer.METHODS: Mammograms and MRI were obtained at baseline and after 1 and 2 years of 60 mg raloxifene by mouth daily for 27 premenopausal women. Mammographic percent dense area was calculated using a semiquantitative thresholding technique. T1-weighted spoiled gradient-echo MRI with fat suppression was used to determine breast MRIV using a semiautomatic method. Mean change in mammographic density and median change in MRIV were assessed by the Wilcoxon signed-rank test.RESULTS: No significant change in mammographic density was seen after treatment with raloxifene. Mean change after 1 year was 1% [95% confidence interval (95% CI), -3 to +5] and after 2 years was 1% (95% CI, -2 to +5). MRIV decreased on raloxifene. Median relative change in MRIV after 1 year was -17% (95% CI, -28 to -9; P = 0.0017) and after 2 years was -16% (95% CI, -31 to -4; P = 0.0004).CONCLUSIONS: In high-risk premenopausal women, mammographic density did not change on raloxifene, whereas MRIV significantly declined. Our findings suggest that MRIV is a promising surrogate biomarker in premenopausal women at increased risk for breast cancer and should be investigated further in breast cancer prevention trials. (Cancer Epidemiol Biomarkers Prev 2008;17(7):OF1-6).



___
Source: http://www.hubmed.org/display.cgi?uids=18583470
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Reply to "ESR1 gene amplification in breast cancer: a common phenomenon?"

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Reply to "ESR1 gene amplification in breast cancer: a common phenomenon?"
To: mesothelioma77@gmail.com


[1]Nat Genet. 2008 Jul; 40(7): 810-812
Holst F, Stahl P, Hellwinkel O, Dancau AM, Krohn A, Wuth L, Heupel C, Lebeau A, Terracciano L, Al-Kuraya K, Jänicke F, Sauter G, Simon R





___
Source: http://www.hubmed.org/display.cgi?uids=18583968
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Magnitude of asbestos-related lung cancer mortality in Italy.

---------- Forwarded message ----------
From: HubMed - asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 28, 2008 at 4:00 PM
Subject: Magnitude of asbestos-related lung cancer mortality in Italy.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Jun 24;
Marinaccio A, Scarselli A, Binazzi A, Mastrantonio M, Ferrante P, Iavicoli S

An ecological study, based on a data set containing all lung and pleural cancer deaths in each Italian municipality in the period 1980-2001, was performed. The pleural to lung cancer ratio was estimated to be 1 : 1 and 3% (around 700) of all male lung cancer deaths were found to be asbestos-related.British Journal of Cancer advance online publication, 24 June 2008; doi:10.1038/sj.bjc.6604450 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18577986
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: EMEA Recommends Information On Lung Cancer Cases To Be Included In Exubera Product Information, Europe (Medical News Today)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: EMEA Recommends Information On Lung Cancer Cases To Be Included In Exubera Product Information, Europe (Medical News Today)
To: mesothelioma77@gmail.com


The European Medicines Agency (EMEA) has recommended that the product information for Exubera be updated with new information on cases of lung cancer seen in patients taking the medicine. Exubera, from Pfizer Limited, is a fast-acting insulin powder for inhalation, used for the treatment of adults with type 1 or type 2 diabetes.

Wed, 18 Jun 2008 09:20:22 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11n9dg9jo/*http%3A//www.medicalnewstoday.com/articles/111649.php
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Lung cancer radiation treatment offers new hope (Daily Telegraph)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Lung cancer radiation treatment offers new hope (Daily Telegraph)
To: mesothelioma77@gmail.com


Lung cancer patients with little chance of survival have been offered new hope with a treatment that targets tumours in the lungs with radiation.

Tue, 17 Jun 2008 23:10:06 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=13rjj8045/*http%3A//www.telegraph.co.uk/news/newstopics/politics/health/2144985/Lung-cancer-radiation-treatment-offers-new-hope.html
--
 
~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Missouri family struggles to stay above water (Los Angeles Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Missouri family struggles to stay above water (Los Angeles Times)
To: mesothelioma77@gmail.com


Sat, 21 Jun 2008 04:57:27 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=1360kmivj/*http%3A//www.latimes.com/news/nationworld/nation/la-na-victims21-2008jun21,0,2600921.story?track=rss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Shannon Boothe Brewer Named a Member of Cambridge Who's Who

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Shannon Boothe Brewer Named a Member of Cambridge Who's Who
To: mesothelioma77@gmail.com

Mrs. Brewer became involved in her profession because she was inspired by a compassionate and dedicated nurse who took care of her grandmother before she lost her battle to lung cancer.

Sat, 21 Jun 2008 06:00:00 GMT

---

Source: http://www.24-7pressrelease.com/press-release-rss/shannon-boothe-brewer-named-a-member-of-cambridge-whos-who-54264.php
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Expression and function of fatty acid amide hydrolase in prostate cancer.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Expression and function of fatty acid amide hydrolase in prostate cancer.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB, Nithipatikom K

The hydrolysis of endocannabinoids has profound effects on the function of the endocannabinoid signaling system in the regulation of prostate carcinoma cells. Prostate carcinoma cells exhibit a wide range of hydrolysis activity for 2-arachidonoylglycerol (2-AG), the major endocannabinoid. However, enzyme(s) responsible for 2-AG hydrolysis and their functions in prostate cancer have not been characterized. In this study, we demonstrated that fatty acid amide hydrolase (FAAH) was differentially expressed in normal and prostate carcinoma cells. In PC-3 cells, overexpression of FAAH resulted in increased FAAH protein, 2-AG hydrolysis, cell invasion and cell migration. Conversely, small-interfering RNA (siRNA) knockdown of FAAH in LNCaP cells decreased FAAH protein, 2-AG hydrolysis and cell invasion. Furthermore, CAY10401, a FAAH inhibitor, decreased cell invasion and it enhanced the reduction of invasion in FAAH siRNA-transfected LNCaP cells. Immunohistochemistry staining of commercial tissue microarrays (TMAs) demonstrated FAAH staining in 109 of 157 cores of prostate adenocarcinomas but weak staining in 1 of 8 cores of normal prostate tissues. These results suggest that FAAH regulates 2-AG hydrolysis and invasion of prostate carcinoma cells and is potentially involved in prostate tumorigenesis. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18566995
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Obituary: Jo Ann Gear loved to share her ceramic skill and art

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Obituary: Jo Ann Gear loved to share her ceramic skill and art
To: mesothelioma77@gmail.com

Jo Ann Gear, who operated a ceramics store and shared her craft with the community, has died at age 59.

Sat, 21 Jun 2008 07:00:00 GMT

---

Source: http://www.sacbee.com/obituaries/story/1029806.html
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Endorectal ultrasonography versus phased-array magnetic resonance imaging for preoperative staging of rectal cancer.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Endorectal ultrasonography versus phased-array magnetic resonance imaging for preoperative staging of rectal cancer.
To: mesothelioma77@gmail.com


[1]World J Gastroenterol. 2008 Jun 14; 14(22): 3504-10
Halefoglu AM, Yildirim S, Avlanmis O, Sakiz D, Baykan A

AIM: To compare the diagnostic accuracy of pelvic phased-array magnetic resonance imaging (MRI) and endorectal ultrasonography (ERUS) in the preoperative staging of rectal carcinoma. METHODS: Thirty-four patients (15 males, 19 females) with ages ranging between 29 and 75 who have biopsy proven rectal tumor underwent both MRI and ERUS examinations before surgery. All patients were evaluated to determine the diagnostic accuracy of depth of transmural tumor invasion and lymph node metastases. Imaging results were correlated with histopathological findings regarded as the gold standard and both modalities were compared in terms of predicting preoperative local staging of rectal carcinoma. RESULTS: The pathological T stage of the tumors was: pT1 in 1 patient, pT2 in 9 patients, pT3 in 21 patients and pT4 in 3 patients. The pathological N stage of the tumors was: pN0 in 19 patients, pN1 in 9 patients and pN2 in 6 patients. The accuracy of T staging for MRI was 89.70% (27 out of 34). The sensitivity was 79.41% and the specificity was 93.14%. The accuracy of T staging for ERUS was 85.29% (24 out of 34). The sensitivity was 70.59% and the specificity was 90.20%. Detection of lymph node metastases using phased-array MRI gave an accuracy of 74.50% (21 out of 34). The sensitivity and specificity was found to be 61.76% and 80.88%, respectively. By using ERUS in the detection of lymph node metastases, an accuracy of 76.47% (18 out of 34) was obtained. The sensitivity and specificity were found to be 52.94% and 84.31%, respectively. CONCLUSION: ERUS and phased-array MRI are complementary methods in the accurate preoperative staging of rectal cancer. In conclusion, we can state that phased-array MRI was observed to be slightly superior in determining the depth of transmural invasion (T stage) and has same value in detecting lymph node metastases (N stage) as compared to ERUS.



___
Source: http://www.hubmed.org/display.cgi?uids=18567078
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Separation and characterization of respirable amphibole fibers from Libby, Montana.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, June 26, 2008 10:12:42 PM
Subject: Separation and characterization of respirable amphibole fibers from Libby, Montana.

[1]Inhal Toxicol. 2008 Jun; 20(8): 733-40
Webber JS, Blake DJ, Ward TJ, Pfau JC

The vermiculite mine in Libby, Montana, was in operation for over 70 yr and was contaminated with asbestos-like amphibole fibers. The mining, processing, and shipping of this vermiculite led to significant fiber inhalation exposure throughout the community, and residents of Libby have developed numerous pulmonary diseases such as lung cancer and mesothelioma. The present study describes the separation of Libby 6-mix into respirable and nonrespirable size fractions by means of aqueous elutriation. The elutriator, designed to separate fibers with aerodynamic diameters smaller than 2.5 microm (respirable) from larger fibers, used an upward flow rate of 3.4 x 10(- 4) cm s(-1). The resultant respirable fraction constituted only 13% of the raw Libby 6-mix mass, and less than 2% of the fibers in the elutriated fraction had aerodynamic diameters exceeding 2.5 microm. Surface area of the elutriated fibers was 5.3 m(- 2) g(-1), compared to 0.53 m(-2) g(-1) for the raw fibers. There were no detectable differences in chemical composition between the larger and smaller fibers. Such harvesting of respirable fractions will allow toxicological studies to be conducted within a controlled laboratory setting, utilizing fiber sizes that may more accurately simulate historical exposure of Libby residents' lungs. Importantly, this work describes a method that allows the use of material enriched in more uniform respirable material than raw Libby 6-mix, making comparisons with other known fiber preparations more valid on a mass basis.



___
Source: http://www.hubmed.org/display.cgi?uids=18569095
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Immunophenotyping of serous carcinoma of the female genital tract.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, June 26, 2008 10:12:42 PM
Subject: Immunophenotyping of serous carcinoma of the female genital tract.

[1]Mod Pathol. 2008 Jun 20;
Nofech-Mozes S, Khalifa MA, Ismiil N, Saad RS, Hanna WM, Covens A, Ghorab Z

To update the data on the expression of 'mesothelioma markers' by serous carcinomas of various sites we have studied cases from ovary (n=56), endometrium (n=37), fallopian tube (n=6), primary peritoneum (n=5) and cervix (n=3) using a panel of antibodies (WT1, P53, estrogen receptors, HER2/neu, D2-40, cytokeratin 5/6 and E-cadherin). Ovarian carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 23.2 and 55.4% of cases, respectively. Endometrial carcinomas demonstrated D2-40 and cytokeratin 5/6 immunoreactivity in 43.2 and 37.8% of cases, respectively. D2-40 staining pattern was predominantly focal; however, strong reactivity was identified in 16.2% of endometrial and 10.7% of ovarian carcinomas. HER2/neu oncoprotein overexpression was demonstrated in 7 of 37 (18.9%) uterine serous carcinomas. In contrast, all the serous carcinomas of the other sites were HER2/neu negative. The proportion of positive cases was significantly different in ovarian vs endometrial carcinomas regarding WT1 (P=0.0458), estrogen receptors (P

___
Source: http://www.hubmed.org/display.cgi?uids=18567994
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Thursday, June 26, 2008 10:12:42 PM
Subject: Phosphorylation and localization of protein-zero related (PZR) in cultured endothelial cells.

[1]Endothelium. 2008 May-Jun; 15(3): 127-36
Kusano K, Thomas TN, Fujiwara K

Protein-zero related (PZR) is an immunoglobulin V (IgV)-type immunoreceptor with two immunoreceptor tyrosine-based inhibitory motifs (ITIMs). PZR interacts with Src homology 2 domain-containing tyrosine phosphatase (SHP-2) via its tyrosine-phosphorylated ITIMs, for which c-Src is a putative kinase. Towards elucidating PZR function in endothelial cells (ECs), the authors cloned PZR from bovine aortic endothelial cells (BAECs) and characterized it. Mature bovine PZR had 94.8% and 92.7% sequence identity with canine and human proteins, respectively, and the two ITIM sequences were conserved among higher vertebrates. PZR was expressed in many cell types and was localized to cell contacts and intracellular granules in BAECs and mesothelioma (REN) cells. Coimmunoprecipitation revealed that PZR, Grb-2-associated binder-1 (Gab1), and platelet endothelial cell adhesion molecule-1 (PECAM-1) were three major SHP-2-binding proteins in BAECs. H(2)O(2) enhanced PZR tyrosine phosphorylation and PZR/SHP-2 interaction in ECs in a dose-and time-dependent manner. To see if tyrosine kinases other than Src are also capable of phosphorylating PZR, the authors cotransfected HEK293 cells with PZR and one of several tyrosine kinases and found that c-Src, c-Fyn, c-Lyn, Csk, and c-Abl, but not c-Fes, phosphorylated PZR and increased PZR/SHP-2 interaction. These results suggest that PZR is a cell adhesion protein that may be involved in SHP-2-dependent signaling at interendothelial cell contacts.



___
Source: http://www.hubmed.org/display.cgi?uids=18568953
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Nevada woman awarded millions in damages against Wyeth dies at 65

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Nevada woman awarded millions in damages against Wyeth dies at 65
To: mesothelioma77@gmail.com

According to her lawyer, Pamela Forrester of Yerington was under hospice care for lung cancer before she died Thursday.

Sat, 21 Jun 2008 21:32:24 GMT

---

Source: http://www.ktnv.com/Global/story.asp?S=8535609
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Personalized medicine initiative targets lung cancer (PhysOrg)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Personalized medicine initiative targets lung cancer (PhysOrg)
To: mesothelioma77@gmail.com


A U.S.-based personalized medicine initiative led by scientists from the Biodesign Institute, Translational Genomics Research Institute (TGen) and Seattle`s Fred Hutchinson Cancer Research Center has secured its first major international collaboration with the government of Luxembourg.

Fri, 20 Jun 2008 18:57:59 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11d4d26ed/*http%3A//www.physorg.com/news133192168.html
--
 ~
 

 

Fwd: Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancer.
To: mesothelioma77@gmail.com


[1]Clin Exp Metastasis. 2008 Jun 20;
Metge BJ, Frost AR, King JA, Dyess DL, Welch DR, Samant RS, Shevde LA

Breast Cancer Metastasis Suppressor 1 (BRMS1) suppresses metastasis of human breast cancer, ovarian cancer and melanoma in athymic mice. Studies have also shown that BRMS1 is significantly downregulated in some breast tumors, especially in metastatic disease. However, the mechanisms which regulate BRMS1 expression are currently unknown. Upon examination of the BRMS1 promoter region by methylation specific PCR (MSP) analysis, we discovered a CpG island (-3477 to -2214), which was found to be hypermethylated across breast cancer cell lines. A panel of 20 patient samples analyzed showed that 45% of the primary tumors and 60% of the matched lymph node metastases, displayed hypermethylation of BRMS1 promoter. Furthermore, we found a direct correlation between the methylation status of the BRMS1 promoter in the DNA isolated from tissues, with the loss of BRMS1 expression assessed by immunohistochemistry. There are several studies investigating the mechanism by which BRMS1 suppresses metastasis; however thus far there is no study that reports the cause(s) of loss of BRMS1 expression in aggressive breast cancer. Here we report for the first time that BRMS1 is a novel target of epigenetic silencing; and aberrant methylation in the BRMS1 promoter may serve as a cause of loss of its expression.



___
Source: http://www.hubmed.org/display.cgi?uids=18566899
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Breast cancer screening in France: results of the EDIFICE survey.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Breast cancer screening in France: results of the EDIFICE survey.
To: mesothelioma77@gmail.com


[1]Int J Med Sci. 2008; 5(3): 106-12
Pivot X, Rixe O, Morere J, Coscas Y, Cals L, Namer M, Serin D, Dolbeault S, Eisinger F, Roussel C, Blay J

BACKGROUND: The EDIFICE survey aimed to investigate the compliance of the general population to the screening tests available in France for the 4 most common cancers: breast, colorectal, prostate and lung. Implementation of breast cancer screening has been generalized in France since 2003: women aged between 50 and 74 years are systematically invited to perform a mammography every second year. Results pertaining to breast cancer are reported hereafter. METHODS: This nationwide observational survey was carried out in France from 18 January to 2 February 2005 among representative samples of 773 women aged between 40 and 75 years and 600 general practitioners (GPs). Information collected included socio-demographic characteristics, attitude towards cancer screening and actual experience of cancer screening, as well as GPs' practice regarding screening. The precision of the results is +/- 4.3% for a 95% confidence interval. RESULTS: Among the 507 participating women aged between 50 and 74 years, 92.5% (469/507) had undergone at least one mammography: 54.6% (256/469) underwent this test on their own initiative and 44.6% (209/469) of women performed it in the framework of a systematic screening plan. Most women participating in the systematic screening (89.0% i.e. 186/209) had a mammography within the last dating from less than 2 years versus 73.8% (189/256) of those who performed it outside the screening program (Chi(2) test; p

___
Source: http://www.hubmed.org/display.cgi?uids=18566655
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Genes controlling spread of breast cancer to lung "gang of 4".

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Genes controlling spread of breast cancer to lung "gang of 4".
To: mesothelioma77@gmail.com


[1]Exp Oncol. 2008 Jun; 30(2): 91-5
Eltarhouny SA, Elsawy WH, Radpour R, Hahn S, Holzgreve W, Zhong XY

Cancer-related mortality is caused in a large part by the metastasis of primary tumor. Each cancer has a particular way of spreading cancerous cells. Recently, genetic and pharmacological analysis identified the set of genes, such as epidermal growth factor receptor ligand epiregulin (EREG), cyclooxygenase-2 (COX2) and matrix metalloproteinases 1 and 2 (MMP-1 and MMP-2) that have been found to be associated with metastasis of breast cancer to lung. Inhibition of EGFR and COX2 could minimize lung metastasis of breast cancer in a clinical setting. In this review, we summarized the current knowledge on EREG, COX2, MMP-1 and MMP-2 in tumor development and metastasis.



___
Source: http://www.hubmed.org/display.cgi?uids=18566569
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Identification Of 5 Genes Involved In The Metastasis Of Breast Tumors To The Lung (Science Daily)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Identification Of 5 Genes Involved In The Metastasis Of Breast Tumors To The Lung (Science Daily)
To: mesothelioma77@gmail.com


Scientists have identified five genes involve in the metastasis of breast tumors to the lung. Of the five genes identified, the Tenascina-C gene seems to be a good therapeutic target for the treatment of metastatic breast cancer. In fact, the blocking of the expression of this gene in the animal model enabled a significant reduction, both in tumour growth and in the incidence of pulmonary ...

Fri, 20 Jun 2008 17:20:32 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=121shd591/*http%3A//www.sciencedaily.com/releases/2008/06/080620115957.htm
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis.
To: mesothelioma77@gmail.com


[1]World J Gastroenterol. 2008 Jun 14; 14(22): 3497-503
Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, Seksik P

AIM: To investigate the phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis (PSC-IBD). METHODS: Data from 75 PSC-IBD patients evaluated in our tertiary center between 1963 and 2006 were collected and compared to 150 IBD patients without PSC, matched for sex, birth date, IBD diagnosis date and initial disease location regarding ileal, different colonic segments, and rectum, respectively. RESULTS: While PSC-IBD patients received more 5-aminosalicylates (8.7 years/patient vs 2.9 years/patient, P

___
Source: http://www.hubmed.org/display.cgi?uids=18567077
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Woman who won millions from Wyeth in cancer suit dies (WDBJ 7 Roanoke)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 22, 2008 at 11:06 PM
Subject: Woman who won millions from Wyeth in cancer suit dies (WDBJ 7 Roanoke)
To: mesothelioma77@gmail.com


RENO, Nev. (AP) - 1 of 3 Nevada women who were awarded millions in damages in a drug-company lawsuit has died. Pamela Forrester was 65-years-old and under hospice care for lung cancer when she died Thursday.

Sun, 22 Jun 2008 05:55:39 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11jj36t46/*http%3A//www.wdbj7.com/Global/story.asp?S=8536903
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Supreme Court rejects W.R. Grace asbestos appeal (Lexington Herald-Leader)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Supreme Court rejects W.R. Grace asbestos appeal (Lexington Herald-Leader)
To: mesothelioma77@gmail.com


The Supreme Court on Monday rejected an appeal by W.R. Grace & Co. in a criminal case brought by the government over the company's alleged release of asbestos from a Montana mine. Federal prosecutors charged the company and six of its executives in February 2005 with violating the Clean Air Act by releasing asbestos from a vermiculite mine in Libby, Mont., even though they allegedly were ...

Mon, 23 Jun 2008 20:34:27 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11h1k75bk/*http%3A//www.kentucky.com/473/story/441632.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Supreme Court rejects W.R. Grace asbestos appeal (AP via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Supreme Court rejects W.R. Grace asbestos appeal (AP via Yahoo! News)
To: mesothelioma77@gmail.com


The Supreme Court on Monday rejected an appeal by W.R. Grace & Co. in a criminal case brought by the government over the company's alleged release of asbestos from a Montana mine.

Mon, 23 Jun 2008 19:41:59 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=1253utrmn/*http%3A//news.yahoo.com/s/ap/20080623/ap_on_bi_ge/scotus_wr_grace_1
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Justices Refuse W.R. Grace Asbestos Appeal (Washington Post)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Justices Refuse W.R. Grace Asbestos Appeal (Washington Post)
To: mesothelioma77@gmail.com


The Supreme Court yesterday declined to hear an appeal by W.R. Grace in a criminal case brought by the government over the company's alleged release of asbestos from a Montana mine.

Tue, 24 Jun 2008 04:07:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12obe7u38/*http%3A//www.washingtonpost.com/wp-dyn/content/article/2008/06/23/AR2008062301977.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Man seeks help in cancer compensation claim (Coventry Observer)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Man seeks help in cancer compensation claim (Coventry Observer)
To: mesothelioma77@gmail.com


A MAN who developed terminal cancer after he was exposed to asbestos at a city insulation company has appealed for help in his battle for compensation.

Mon, 23 Jun 2008 14:45:32 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=11khsr8h2/*http%3A//www.coventryobserver.co.uk/news48295.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Supreme Court rejects W.R. Grace asbestos appeal (San Francisco Chronicle)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Supreme Court rejects W.R. Grace asbestos appeal (San Francisco Chronicle)
To: mesothelioma77@gmail.com


The Supreme Court on Monday rejected an appeal by W.R. Grace & Co. in a criminal case brought by the government over the company's alleged release of asbestos from a Montana mine. Federal prosecutors charged the company and six of its executives in February...

Mon, 23 Jun 2008 20:03:45 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=13aq1g0pt/*http%3A//www.sfgate.com/cgi-bin/article.cgi?f=/n/a/2008/06/23/financial/f124204D27.DTL&feed=rss.business
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: The Mesothelioma Victims Center Encourages Victims Of Asbestos-Related Cancer To Avoid Help Web Sites That Are Little ... (PRWeb via Yahoo! News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: The Mesothelioma Victims Center Encourages Victims Of Asbestos-Related Cancer To Avoid Help Web Sites That Are Little ... (PRWeb via Yahoo! News)
To: mesothelioma77@gmail.com


Americas Watchdog created the Mesothelioma Center as a way for victims of Mesothelioma or their friends or family to get honest answers.

Mon, 23 Jun 2008 07:01:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=1222u523b/*http%3A//news.yahoo.com/s/prweb/20080623/bs_prweb/prweb1043634_1
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Workers exposed to asbestos: WorkSafeBC (Richmond News)

---------- Forwarded message ----------
From: Yahoo! News Search Results for asbestos cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Workers exposed to asbestos: WorkSafeBC (Richmond News)
To: mesothelioma77@gmail.com


In a quiet Richmond neighbourhood, a house being prepared for demolition is fenced off. Orange tarps contain the home and a large garbage skip sits in the driveway.

Tue, 24 Jun 2008 07:09:52 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/asbestos+cancer/SIG=12u1r5884/*http%3A//www.canada.com/richmondnews/news/story.html?id=c6a8cbe9-0d01-4457-8ef2-b0722de59320
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Workers exposed to asbestos...

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Tue, Jun 24, 2008 at 6:16 AM
Subject: Workers exposed to asbestos...
To: mesothelioma77@gmail.com

In a quiet Richmond neighbourhood, a house being prepared for demolition is fenced off.

Tue, 24 Jun 2008 10:05:03 GMT

---

Source: http://www.canada.com/richmondnews/news/story.html?id=c6a8cbe9-0d01-4457-8ef2-b0722de59320
--
 Powered by RssFwd, a service of Blue Sky Factory, Inc

Fw: Man Dies After Lung Removal, Wrong Cancer Diagnosis

----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:01:42 AM
Subject: Man Dies After Lung Removal, Wrong Cancer Diagnosis

A 61-year-old man died after doctors allegedly wrongly diagnosed him with lung cancer and removed a healthy lung in an attempt to help him live longer, the Daily Mail reported on Wednesday.

Thu, 05 Jun 2008 16:06:02 GMT

___
Source: http://www.foxnews.com/story/0,2933,363469,00.html
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fw: Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: A case report.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:25 AM
Subject: Cytomorphologic features of well-differentiated papillary mesothelioma in peritoneal effusion: A case report.

[1]Diagn Cytopathol. 2008 Jun 4; 36(7): 512-515
Ikeda K, Suzuki T, Tate G, Mitsuya T

Well-differentiated papillary mesothelioma (WDPM), a distinct subtype of diffuse malignant mesothelioma, usually occurs in the peritoneum and is seen most commonly in women of reproductive age. Histologic features of WDPM include papillary growth and stout fibrous cores surrounded by a single layer of tumor cells. We present the case of a 73-year-old woman without subjective symptoms who showed signs of peritoneal effusion during a routine examination and for whom cytologic examination of the ascitic fluid was performed. Many spherical clusters, with a smooth external surface composed of a single layer of uniform cuboidal cells, were observed. Within each cluster, a collagenous ball showed light green Papanicolaou staining. Immunohistochemistry of surgical specimens showed tumor cells positive for calretinin, D(2)-40, and HBME-1 staining. The histologic diagnosis was WDPM. The identification of a collagenous ball within these clusters is a useful cytologic finding for the diagnosis of WDPM. WDPM should be suspected when numerous collagenous balls are present by effusion cytology and isolated cells are not. Diagn. Cytopathol. 2008;36:512-515. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18528881
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: 'It was agonising watching him suffer'

----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:01:42 AM
Subject: 'It was agonising watching him suffer'

In a landmark case starting this week, insurance companies are being sued for refusing to pay compensation to asbestos victims and their families.

Tue, 03 Jun 2008 06:51:37 GMT

___
Source: http://news.bbc.co.uk/1/hi/health/7431979.stm
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fw: Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:25 AM
Subject: Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine.

[1]Oncology. 2008 Jun 3; 73(5-6): 426-429
Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME

We report the case of a 56-year-old patient with malignant pleural mesothelioma of epithelial type, who responded to second-line chemotherapy with lipoplatin plus gemcitabine. Diagnosis and staging of the disease was done by medical thoracoscopy with biopsies of the right pleura in December 2003, when he was treated with talc pleurodesis. Eighteen months later, he presented with pleural effusion of the left side and underwent first-line chemotherapy with cisplatin plus vinorelbine. After 8 cycles, the patient presented renal toxicity limiting further cisplatinum chemotherapy and disease progression with peritoneal invasion of the tumor and ascites. Treatment with lipoplatin-gemcitabine was decided on in November 2006, and the patient showed important improvement in the clinical status and peritoneal effusion. He survived for 36 weeks, with symptom-free survival of 34 weeks.



___
Source: http://www.hubmed.org/display.cgi?uids=18523361
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Diagnostic usefulness and challenges in the diagnosis of mesothelioma by endoscopic ultrasound guided fine needle aspiration.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:25 AM
Subject: Diagnostic usefulness and challenges in the diagnosis of mesothelioma by endoscopic ultrasound guided fine needle aspiration.

[1]Diagn Cytopathol. 2008 Jun 4; 36(7): 503-507
Bakdounes K, Jhala N, Jhala D

Malignant mesothelioma is a rare neoplasm. It has been noted in the literature that fine needle aspiration (FNA) is a useful tool for the diagnosis of mesothelioma. However, the differential diagnosis may require use of a battery of immunohistochemical stains. Clinico-radiologic correlation is also crucial. Real time endoscopic ultrasound (EUS) combined with FNA has been shown to be a very sensitive technique to obtain samples from different organ sites, including mediastinal lesions. The use of EUS-FNA for the diagnosis of mesothelioma, reinforces the role of a cytopathologist as a cohesive team player along with a radiologist and a clinician during on-site assessment for the proper triage of additional specimens for ancillary studies leading to a better patient management. Diagn. Cytopathol. 2008;36:503-507. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18528879
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: [An autopsy case of diffuse pleural thickening presented respiratory impairment and benign asbestos pleurisy]

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:25 AM
Subject: [An autopsy case of diffuse pleural thickening presented respiratory impairment and benign asbestos pleurisy]

[1]Nihon Kokyuki Gakkai Zasshi. 2008 May; 46(5): 368-73
Morokawa N, Takayanagi N, Ubukata M, Kurashima K, Yoned K, Tsuchiy N, Miyahara Y, Yamaguchi S, Tokunaga D, Saito H, Yanagisawa T, Sugita Y, Kawabata Y

A 51-year-old man presented with back pain in 1997. He had a 30-year-history of occupational asbestos exposure. His chest CT showed bilateral pleural thickening and pleural effusion. The pleural effusion of the right thorax exhibited both elevated level of adenosine deaminase and increased numbers of lymphocytes. Antituberculous chemotherapy had no effect on the exudates. Progressive bilateral pleural thickening were found on chest CT, and pulmonary function tests showed severe restrictive ventilatory impairments since 1998. Thoracoscopic pleural biopsy was conducted in 2001 to exclude pleural malignant mesothelioma. No malignancy was found in pleural samples. After 3-year observation and excluding other causes, he was given a diagnosis of benign asbestos pleurisy. In 2005, fibrotic changes were found in both lower lung fields in chest CT. He suffered from respiratory failure with carbon dioxide retention, and died in 2006. The autopsy disclosed asbestos-related lung diseases. We suspected that diffuse pleural thickening could be a major cause of fatal respiratory impairment in this case.



___
Source: http://www.hubmed.org/display.cgi?uids=18517012
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Image-guided pleural biopsy.

----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:25 AM
Subject: Image-guided pleural biopsy.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 331-6
Rahman NM, Gleeson FV

PURPOSE OF REVIEW: Pleural diseases are a common and increasing clinical problem. Establishing accurate diagnosis is an essential step in management of these patients, and approximately 40% of pleural effusions will remain undiagnosed after initial diagnostic thoracocentesis. Obtaining pleural tissue (by blind, image-guided or thoracoscopic pleural biopsy) is therefore a key procedure. Recent evidence provides important information on the relative value of each of these techniques. RECENT FINDINGS: For the diagnosis of malignant pleural disease, both thoracoscopic and image-guided biopsy have a far higher diagnostic yield than blind pleural biopsy. Cutting needle biopsies have a higher diagnostic yield in malignancy (and especially mesothelioma) compared with fine needle aspiration. The complication rate of image-guided biopsy is low. Rates of biopsy site tract invasion by mesothelioma may be lower using smaller biopsy ports, as used for image-guided pleural biopsy. SUMMARY: Blind pleural biopsy should no longer be conducted for the study of malignant pleural disease if facilities for other techniques are available. Image-guided and thoracoscopic biopsies have similarly high diagnostic rates, and are complementary techniques used in different clinical situations. Further studies assessing biopsy tract site invasion from mesothelioma with different biopsy techniques are required.



___
Source: http://www.hubmed.org/display.cgi?uids=18520268
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: The relationship between simian virus 40 and mesothelioma.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: The relationship between simian virus 40 and mesothelioma.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 316-321
Rivera Z, Strianese O, Bertino P, Yang H, Pass H, Carbone M

PURPOSE OF REVIEW: Simian virus 40 is present in some human malignant mesotheliomas. The evidence in favor and against a pathogenic role of simian virus 40 in malignant mesothelioma is discussed in this review. RECENT FINDINGS: When simian virus 40 is injected intracardially into hamsters, 60% develop and die of malignant mesothelioma. Moreover, some human malignant mesotheliomas contain and express simian virus 40 DNA and proteins. To date, over 50 laboratories have detected simian virus 40 in malignant mesotheliomas and in other tumors; however, the variability of the percentage of positivity led to a controversy about the role and significance of simian virus 40 in malignant mesotheliomas. Compared with other cell types, human mesothelial cells are unusually susceptible to simian virus 40-induced malignant transformation. The presence of simian virus 40 in malignant mesothelioma has been associated with the activation of specific oncogene pathways. Cocarcinogenesis between simian virus 40 and asbestos in causing malignant mesotheliomas has been demonstrated in three separate research laboratories using different experimental approaches. Epidemiological data possibly linking simian virus 40 and malignant mesothelioma is lacking owing to unattainable identification of infected from noninfected cohorts. SUMMARY: Available evidence appears sufficient to link simian virus 40 either alone or in conjunction with asbestos in causing malignant mesotheliomas; however, it is still insufficient to speculate about the contribution of simian virus 40 to the overall incidence of malignant mesotheliomas.



___
Source: http://www.hubmed.org/display.cgi?uids=18520265
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Mesothelioma due to environmental exposure to erionite in Turkey.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Mesothelioma due to environmental exposure to erionite in Turkey.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 322-5
Dikensoy O

PURPOSE OF REVIEW: The prevalence of malignant mesothelioma due to erionite exposure in Central Anatolia is very high. In this report, we review the recent developments on this epidemic on the basis of previous literature. RECENT FINDINGS: Recently, it has been shown that erionite is poorly cytotoxic, induces proliferating signals and high growth rate in human mesothelial cells. Additionally, long-term exposure to erionite transforms human mesothelial cells in vitro, regardless of the presence of Simian Virus 40 sequences, leading to foci formation in cultured monolayers. It has also been confirmed that a genetic predisposition to erionite carcinogenesis is the cause of the mesothelioma epidemic in Cappadocia. SUMMARY: The data obtained recently on the epidemiology, etiology, and pathogenesis of the mesothelioma due to erionite exposure in Turkey are described.



___
Source: http://www.hubmed.org/display.cgi?uids=18520266
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 326-30
Davies HE, Musk AW, Lee YG

PURPOSE OF REVIEW: Malignant mesothelioma is a uniformly fatal disease and active supportive care, minimizing patient morbidity, remains the accepted standard treatment. Tract metastases in patients with mesothelioma are a well recognized complication of pleural intervention and prophylactic radiotherapy is commonly implemented to prevent their occurrence. This review critically analyzes the published literature to establish the role of prophylactic radiotherapy to pleural puncture sites and highlights controversies that exist. RECENT FINDINGS: Current practice is based on a clinical study published in 1995. However, two recent randomized controlled trials did not support the widely held belief that all patients undergoing diagnostic or therapeutic pleural puncture should receive prophylactic drain site irradiation. Data assessing the incidence of associated morbidity from tract metastases suggest that rates are lower than previously thought. SUMMARY: The routine administration of radiotherapy in all patients with mesothelioma following pleural intervention remains debated. Instead of prophylactic irradiation, directing surveillance toward patients with large (e.g. thoracoscopic) pleural puncture sites and reserving treatments to symptomatic deposits may be more appropriate. This strategy would optimize patient care and minimize hospital visits, but allow prompt instigation of treatment if symptoms develop.



___
Source: http://www.hubmed.org/display.cgi?uids=18520267
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Image-guided pleural biopsy.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Image-guided pleural biopsy.

[1]Curr Opin Pulm Med. 2008 Jul; 14(4): 331-6
Rahman NM, Gleeson FV

PURPOSE OF REVIEW: Pleural diseases are a common and increasing clinical problem. Establishing accurate diagnosis is an essential step in management of these patients, and approximately 40% of pleural effusions will remain undiagnosed after initial diagnostic thoracocentesis. Obtaining pleural tissue (by blind, image-guided or thoracoscopic pleural biopsy) is therefore a key procedure. Recent evidence provides important information on the relative value of each of these techniques. RECENT FINDINGS: For the diagnosis of malignant pleural disease, both thoracoscopic and image-guided biopsy have a far higher diagnostic yield than blind pleural biopsy. Cutting needle biopsies have a higher diagnostic yield in malignancy (and especially mesothelioma) compared with fine needle aspiration. The complication rate of image-guided biopsy is low. Rates of biopsy site tract invasion by mesothelioma may be lower using smaller biopsy ports, as used for image-guided pleural biopsy. SUMMARY: Blind pleural biopsy should no longer be conducted for the study of malignant pleural disease if facilities for other techniques are available. Image-guided and thoracoscopic biopsies have similarly high diagnostic rates, and are complementary techniques used in different clinical situations. Further studies assessing biopsy tract site invasion from mesothelioma with different biopsy techniques are required.



___
Source: http://www.hubmed.org/display.cgi?uids=18520268
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Word of Mouse Issue 30

----- Forwarded Message ----
From: Search for mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, June 20, 2008 4:31:42 AM
Subject: Word of Mouse Issue 30

In his essay, The Median Isn't the Message , Stephen Jay Gould recalls that when he was first diagnosed with abdominal mesothelioma, a rare form of cancer, his consultant suggested that maybe he shouldn't read ...

Wed, 18 Jun 2008 09:52:50 GMT

___
Source: http://www.philosophersnet.com/magazine/article.php?id=851
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fw: [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 22, 2008 10:52:17 PM
Subject: [Chemotherapy of malignant pleural mesothelioma: have we made any progress?]

[1]Zentralbl Chir. 2008 Jun; 133(3): 238-42
Reck M, Heigener DF, Gatzemeier U

Chemotherapy of malignant mesothelioma is of great importance because most patients with malignant pleural mesothelioma are diagnosed for the first time with widespread or advanced disease. Due to the small number of patients in clinical trials and due to difficulties in tumour assessment in the last 20 years, validation criteria for efficacy could only be defined with major limitations. After the introduction of modern antifolates in the chemotherapy for malignant mesothelioma and after the establishment of standardised response criteria, a significant prolongation of survival time by combination chemotherapy was shown in two randomised phase III trials. The combination of pemetrexed and cisplatin is the current standard of chemotherapy in malignant mesothelioma. Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients. In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.



___
Source: http://www.hubmed.org/display.cgi?uids=18563688
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: [Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy.]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 22, 2008 10:52:17 PM
Subject: [Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy.]

[1]Zentralbl Chir. 2008 Jun; 133(3): 231-237
Sienel W, Kirschbaum A, Passlick B

Multimodal therapy including neoadjuvant chemotherapy with subsequent extrapleural pneumonectomy and postoperative radiotherapy has been shown to improve the survival of patients with malignant pleural mesothelioma (MPM) if they are selected carefully. Careful patient selection is required in order to administer aggressive multimodal therapy only to patients who will benefit from such a treatment. To achieve an accurate staging (

___
Source: http://www.hubmed.org/display.cgi?uids=18563687
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: [Mesothelioma: a still current occupational cancer]

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Sunday, June 22, 2008 10:52:17 PM
Subject: [Mesothelioma: a still current occupational cancer]

[1]Rev Med Liege. 2008 Mar; 63(3): 128-35
Corhay JL, Duysinx B, Louis R

Mesothelioma is a rare tumour, particularly aggressive, whose incidence increases because of the massive use of asbestos during the last century. Asbestos remains indeed the principal etiologic agent of this cancer. In the event of mesothelioma it is advisable to seek an exposure, even of short duration, often which dates back to several decades. In certain circumstances compensation can be obtained at the Occupational Diseases Found. The renewed interest with regard to this tumour is supported by the improvement of mesothelioma management, the new imaging techniques, the new treatments and the broad diffusion of information related to the risk of developing this tumour following asbestos inhalation.



___
Source: http://www.hubmed.org/display.cgi?uids=18561768
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Pleural Mesothelioma Diagnosis - Family Reaction

---------- Forwarded message ----------
From: blinkx SmartFeed: mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Tue, May 6, 2008 at 8:34 PM
Subject: Pleural Mesothelioma Diagnosis - Family Reaction
To: collegeschoolloan@gmail.com


In 2001 Joe Trocki was diagnosed with pleural mesothelioma. In this video his daughter Patti shares how the family reacted. For more information visit:...

smartfeed@blinkx.com Mon, 05 May 2008 19:45:20 GMT

___
Source: http://www.blinkx.com/video/YouTube/Pleural_Mesothelioma_Diagnosis_-_Family_Reaction~vqSHeZvpkrrgnNk54JhmXMw&referrer=website_rss
--
 ~
Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Palace of Westminster Asbestos Problem Ignored (PR Newswire via Yahoo! Finance)

---------- Forwarded message ----------
From: Yahoo! News Search Results for mesothelioma diagnosis <rssfwd@rssfwd.com>
Date: Wed, Jun 18, 2008 at 9:55 AM
Subject: Palace of Westminster Asbestos Problem Ignored (PR Newswire via Yahoo! Finance)
To: collegeschoolloan@gmail.com


Clinica - the world's leading news service for the medical technology industry - has learned that staff and visitors to London's Houses of Parliament have been at risk of exposure to high levels of asbestos contamination for significant periods during the last three years.

Tue, 17 Jun 2008 09:26:00 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/mesothelioma+diagnosis/SIG=12146ord8/*http%3A//biz.yahoo.com/prnews/080617/3682401en_public.html?.v=1
--
 

Fwd: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.
To: mesothelioma77@gmail.com


[1]Radiology. 2008 Jul; 248(1): 79-87
Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM

PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging. MATERIALS AND METHODS: This retrospective study was approved by the institutional review board and was HIPAA compliant; informed consent was waived. From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers. Forty-eight women (mean age, 49.1 years; range, 29.7-72.4 years) were divided into recurrence-free or recurrence groups. Volume measurements were tabulated for SER values between set ranges; cutoff criteria were defined to predict disease recurrence after surgery. Wilcoxon rank sum tests and the multivariate Cox proportional hazards regression model were used for evaluation. RESULTS: Breast tumor volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in benign tumors (0.88 minutes(-1)) and the volume of cancerous breast tissue infiltrating into the parenchyma were important predictors of disease recurrence. Seventy-five percent of patients with recurrence and 100% of deceased patients were identified as being at high risk for recurrence. Thirty percent of patients with recurrence and 67% of deceased patients were identified as having high risk before chemotherapy. No patients in the recurrence-free group were misidentified as likely to have recurrence. All three prechemotherapy parameters (total tumor volume, tumor volumes with high and low SER) and the postchemotherapy tumor volume with high SER were significantly different between the two groups. The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER tumor volumes (P = .017 and .049, respectively) were significant and independent predictors of tumor recurrence. Tumor volume with high SER was the only significant postchemotherapy covariate predictor (P = .038). CONCLUSION: High-spatial-resolution SER imaging may improve prediction for patients at high risk for disease recurrence and death.



___
Source: http://www.hubmed.org/display.cgi?uids=18566170
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: [Lung tumours, primary and secondary]

---------- Forwarded message ----------
From: HubMed - asbestos cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:02 PM
Subject: [Lung tumours, primary and secondary]
To: mesothelioma77@gmail.com


[1]Rev Prat. 2008 Feb 29; 58(4): 435-43
Urban T, Hureaux J, Leguen Y





___
Source: http://www.hubmed.org/display.cgi?uids=18506986
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Ghadersohi A, Odunsi K, Zhang S, Azrak RG, Bundy BN, Manjili MH, Li F

We have previously shown that ovarian tumors express prostate-derived Ets transcription factor (PDEF). However, the precise role of PDEF in the prognosis of ovarian cancer is unknown. In our study, we report for the first time that expression of PDEF in tumor lesions of patients with ovarian cancer is associated with favorable prognosis. Evaluation of samples from 40 patients with ovarian cancer showed that early stage (IA) and borderline (IIB, III) ovarian tumors expressed higher levels of PDEF mRNA and protein and lower levels of survivin compared to late stage ovarian tumors (IIIC and IV, p

___
Source: http://www.hubmed.org/display.cgi?uids=18567002
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Family history of cancer and stomach cancer risk.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jun 21, 2008 at 6:01 PM
Subject: Family history of cancer and stomach cancer risk.
To: mesothelioma77@gmail.com


[1]Int J Cancer. 2008 Jun 19;
Foschi R, Lucenteforte E, Bosetti C, Bertuccio P, Tavani A, La Vecchia C, Negri E

A family history of stomach cancer in first-degree relatives increases the risk of stomach cancer, but uncertainties remain as concerns the variation of the risk according to age, sex and type of relative, as well as on the role of family history of other cancers. We investigated the issue using data from a multicentric case-control study conducted in Italy between 1997 and 2007 on 230 cases aged not more than 80 years, with histologically confirmed incident gastric cancer and 547 controls admitted to hospital for acute, non neoplastic conditions. Logistic regression models adjusted for the effect of sex, age, year of interview, education, body mass index (BMI), tobacco smoking and number of brothers and sisters were used to estimate the odds ratios (OR) of stomach cancer. Relative to subjects with no history, those with a family history of gastric cancer had an OR of 2.5 (95% confidence interval (CI) 1.5-4.2). No significant heterogeneity emerged according to sex or age of the proband or of the affected relative, or smoking habits, BMI and education of the proband. As suggested from previous studies the OR was higher when the affected relative was a sibling (OR=5.1, 95% CI: 1.3-20.6) rather than a parent (OR=2.2, 95% CI: 1.2-3.9), although the heterogeneity test was not significant. The risk of stomach cancer was not increased in subjects with a family history of cancer at any other site. The OR for all sites excluding stomach was 1.0 (95% CI: 0.7-1.4). (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18567000
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Excess of Mesotheliomas after Exposure to Chrysotile in Balangero, Italy.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Excess of Mesotheliomas after Exposure to Chrysotile in Balangero, Italy.

[1]Occup Environ Med. 2008 Jun 4;
Mirabelli D, Calisti R, Barone Adesi F, Fornero E, Merletti F, Magnani C

CONTEXT: Chrysotile from the mine in Balangero, Italy, is considered to be tremolite-free. In a cohort study of miners and millers only two pleural cancers were reported, a finding considered to contribute evidence that chrysotile has a low potency for inducing mesothelioma. However, follow-up ended in 1987 and white-collar workers and employees of sub-contractors were not studied. Population and METHODS: To complete the case ascertainment, we searched the Registry of Malignant Mesotheliomas of Piedmont for records of cases among: mine employees; employees of subcontractors or of other firms transporting or refining Balangero asbestos, asbestos ore or mine tailings; individuals exposed to air pollution from the mine or living with mine employees; and individuals exposed to mine tailings from Balangero. RESULTS: We identified 4 new cases of pleural mesothelioma among blue-collar workers in the mine, in addition to the two reported in the cohort study. Thus, 6 mesotheliomas occurred, compared to 1.5 expected (p 

___
Source: http://www.hubmed.org/display.cgi?uids=18524838
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Uroplakin is not a Reliable Immunohistochemical Marker for Malignant Mesothelioma of the Pleura.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Uroplakin is not a Reliable Immunohistochemical Marker for Malignant Mesothelioma of the Pleura.

[1]Appl Immunohistochem Mol Morphol. 2008 Jun 3;
Butnor KJ, Ordonez NG

AIM: To analyze the immunohistochemical expression of uroplakin (URO) in pleural malignant mesothelioma (PMM). METHODS AND RESULTS: We analyzed URO expression in PMM using similar immunohistochemical techniques at 2 separate institutions. At an antibody dilution of 1:10, 0/5 PMMs were immunoreactive for URO. At 1:8, diffuse weak cytoplasmic staining was seen in all 38 PMMs tested, but no membrane staining was observed. Adjacent nontumor tissue and positive control tissue showed cytoplasmic staining of equivalent intensity. Similar staining results were observed in 27 PMMs at a 1:5 dilution. CONCLUSIONS: At an antibody dilution for which positive and negative control tissues stain appropriately, PMM does not stain for URO. At higher antibody concentrations, PMM exhibits nonspecific cytoplasmic staining. We assert that URO is not a useful immunohistochemical marker for the detection of PMM. Further studies addressing whether URO is overexpressed at the mRNA level in PMM are warranted.



___
Source: http://www.hubmed.org/display.cgi?uids=18528285
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Diagnostic usefulness and challenges in the diagnosis of mesothelioma by endoscopic ultrasound guided fine needle aspiration.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Diagnostic usefulness and challenges in the diagnosis of mesothelioma by endoscopic ultrasound guided fine needle aspiration.

[1]Diagn Cytopathol. 2008 Jun 4; 36(7): 503-507
Bakdounes K, Jhala N, Jhala D

Malignant mesothelioma is a rare neoplasm. It has been noted in the literature that fine needle aspiration (FNA) is a useful tool for the diagnosis of mesothelioma. However, the differential diagnosis may require use of a battery of immunohistochemical stains. Clinico-radiologic correlation is also crucial. Real time endoscopic ultrasound (EUS) combined with FNA has been shown to be a very sensitive technique to obtain samples from different organ sites, including mediastinal lesions. The use of EUS-FNA for the diagnosis of mesothelioma, reinforces the role of a cytopathologist as a cohesive team player along with a radiologist and a clinician during on-site assessment for the proper triage of additional specimens for ancillary studies leading to a better patient management. Diagn. Cytopathol. 2008;36:503-507. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18528879
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fw: Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.

----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Saturday, June 7, 2008 2:02:29 AM
Subject: Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance.

[1]Int J Cancer. 2008 Jun 4;
Barone-Adesi F, Ferrante D, Bertolotti M, Todesco A, Mirabelli D, Terracini B, Magnani C

Models based on the multistage theory of carcinogenesis predict that the rate of mesothelioma increases monotonically as a function of time since first exposure (TSFE) to asbestos. Predictions of long-term mortality (TSFE >/= 40 years) are, however, still untested, because of the limited follow-up of most epidemiological studies. Some authors have suggested that the increase in mesothelioma rate with TSFE might be attenuated by clearance of asbestos from the lungs. We estimated mortality time trends from pleural and peritoneal cancer in a cohort of 3,443 asbestos-cement workers, followed for more than 50 years. The functional relation between mesothelioma rate and TSFE was evaluated with various regression models. The role of asbestos clearance was explored using the traditional mesothelioma multistage model, generalized to include a term representing elimination over time. We observed 139 deaths from pleural and 56 from peritoneal cancer during the period 1950-2003. The rate of pleural cancer increased during the first 40 years of TSFE and reached a plateau thereafter. In contrast, the rate of peritoneal cancer increased monotonically with TSFE. The model allowing for asbestos elimination fitted the data better than the traditional model for pleural (p = 0.02) but not for peritoneal cancer (p = 0.22). The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs. (c) 2008 Wiley-Liss, Inc.



___
Source: http://www.hubmed.org/display.cgi?uids=18528868
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Intraoperative identification of suspicious palpable lymph nodes as an integral part of sentinel node biopsy in patients with breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Jun 20, 2008 at 4:49 AM
Subject: Intraoperative identification of suspicious palpable lymph nodes as an integral part of sentinel node biopsy in patients with breast cancer.
To: mesothelioma77@gmail.com


[1]Surg Today. 2008; 38(5): 390-4
Choi YJ, Kim JH, Nam SJ, Ko YH, Yang JH

PURPOSE: Despite the sensitivity and accuracy of sentinel lymph node biopsy (SLNB), the number of false negative (FN) results is still relatively high, which has prompted much investigation. We studied the effectiveness of the biopsy of suspicious palpable lymph nodes (LNs) in reducing the number of FN results. METHODS: We reviewed the medical records of 865 breast cancer patients who underwent successful SLNB at a single institution. After excising the blue-stained or radioactive nodes, all suspicious palpable LNs that were not either blue-stained or radioactive were also excised. RESULTS: Sampling of a suspicious palpable LN was done in 342 (39.5%) of the 865 patients. The average number of suspicious palpable nodes was 1.9. The suspicious nodes harbored metastasis in 19 of the 342 patients. Both blue-stained and radioactive metastatic SLNs were found in 8 patients, whereas the palpable nodes were the only ones involved in the other 11. LN involvement was identified solely by biopsy of a suspicious palpable LN in 11 (6.5%) of 170 patients with SLN metastasis (6.5%). CONCLUSION: Biopsy of a suspicious palpable LN should be done as part of SLNB to reduce the number of FN results of SLNs in breast cancer patients.



___
Source: http://www.hubmed.org/display.cgi?uids=18560959
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc